SSCRIMED
Healthcare buyerUnderstand SCRIMED quicklyDemo, pilot, or pricing ownerConvert demo interest into a priced pilot pathInvestor, strategic partner, or faith-based clinic sponsorUnderstand SCRIMED's investable and sellable value safely
Hub

Investor and audience readiness

SCRIMED now turns weaknesses into owned relief tracks and investor-ready audience packets.

This control plane packages angel, corporate strategic, private investor, faith-based clinic, health system, payer, public-sector, clinician, global partner, and transformation-sponsor paths while preserving no-securities, no-solicitation, no-tax-advice, no-PHI, and no-live-care boundaries.

Download Audience BriefInspect APICapital VitalityGrowth EngineBusiness Ops
Statusinvestor-audience-readiness-control-plane-active
Weakness tracks10
High severity4
Edge signals8
Audience packets10
Ready now4
Package next3
External review3
Readiness gates8
Blocked claims65
Strategic targets4
Diligence ready3
Review still required5

Boundary

Investment and audience preparation stays powerful because it does not overstep authority.

SCRIMED Investor and Audience Readiness organizes weakness relief, competitive differentiation, sellable value, and investor or buyer audience packets for readiness review. It is operating-readiness material only. It is not investment advice, securities offering material, audited financial reporting, valuation assurance, legal advice, tax advice, accounting advice, solicitation, private placement approval, Form D filing, crowdfunding approval, nonprofit tax advice, donor advice, faith-based endorsement, customer revenue guarantee, profit guarantee, reimbursement assurance, security certification, regulatory approval, PHI processing approval, production connector approval, or live clinical care authorization.

01not-securities-offering-material
02not-solicitation
03qualified-review-required
04not-authorized-production-phi

Strategic outreach

Four company-specific theses replace generic logo outreach.

Each path names the official ecosystem program, a specific evidence-backed ask, the proof routes to open, and the claims that must stay blocked. No outreach has been sent and no investment or partnership is implied.

packet-review-required

OpenAI

SCRIMED is not a chatbot wrapper; it is a healthcare intelligence control plane that can route frontier models without assigning them autonomous clinical authority.

Request a startup or healthcare ecosystem fit conversation, technical architecture feedback, and the correct path for future commercial or strategic engagement.
  • Strategic fit: Governed, model-agnostic healthcare workflow orchestration can demonstrate how frontier reasoning is bounded by evidence, verification, human approval, and durable audit controls.
  • Official path: OpenAI for Startups and OpenAI for Healthcare
  • Proof: /scrimed-work, /clinical-robustness-lab, /trust-os, /documentation-before-authorization
  • Diligence: Provider-neutral architecture diagram, Clinical safety and no-PHI boundary evidence, Evaluation and verification results, Measured pilot economics methodology
  • Boundary: Do not imply OpenAI investment, endorsement, healthcare validation, model exclusivity, or provider approval.
research-ready

NVIDIA

The strategic wedge is an auditable healthcare compute fabric spanning cloud, customer VPC, air-gapped, and edge deployment modes without claiming final imaging interpretation.

Prepare an Inception application and request technical guidance on healthcare inference, edge deployment, benchmarking, and partner ecosystem fit.
  • Strategic fit: SCRIMED's private and edge compute roadmap, imaging metadata layer, model benchmarking, and healthcare deployment profiles align with accelerated inference and governed hospital infrastructure needs.
  • Official path: NVIDIA Inception
  • Proof: /enterprise-healthcare-infrastructure, /scrimed-clinical-benchmark-suite, /interoperability, /investor-readiness
  • Diligence: Compute and deployment architecture, Benchmark methodology, Edge/private inference threat model, GPU economics assumptions labeled as modeled
  • Boundary: Do not imply NVIDIA investment, Inception acceptance, hardware validation, medical-device capability, or production deployment approval.
packet-review-required

Anthropic

SCRIMED can be a healthcare-specific proof point for controlled agentic work where retrieved content is untrusted and every consequential action is independently reviewed.

Request program eligibility guidance, technical safety feedback, and the appropriate path for future partner or startup engagement.
  • Strategic fit: SCRIMED's governed MCP gateway, agent policy controls, prompt-injection defenses, verification-first orchestration, and long-running work sessions align with dependable enterprise agent deployment.
  • Official path: Anthropic Startup Program and Claude Partner Network
  • Proof: /scrimed-work, /scrimed-agent-governance, /scrimed-trustops, /trust-center
  • Diligence: MCP and tool-permission architecture, Agent evaluation and loop-guard evidence, Prompt-injection threat controls, Human approval and rollback evidence
  • Boundary: Do not imply Anthropic investment, program acceptance, partner status, model safety certification, or exclusive provider alignment.
research-ready

Microsoft

The partnership story is enterprise healthcare workflow intelligence with tenant isolation, FHIR-ready context, security evidence, and staged deployment controls.

Prepare a startup application and request architecture, marketplace, healthcare ecosystem, and enterprise go-to-market guidance.
  • Strategic fit: SCRIMED's enterprise identity, interoperability, governed deployment, buyer diligence, and health-system workflow architecture can map to future Azure-aligned pilots without creating a cloud dependency.
  • Official path: Microsoft for Startups
  • Proof: /interoperability, /enterprise-healthcare-infrastructure, /enterprise-business-ops, /pilot-demo-commercial-readiness
  • Diligence: Enterprise deployment diagram, Identity and tenant-isolation evidence, Interoperability conformance roadmap, Procurement and pilot activation plan
  • Boundary: Do not imply Microsoft investment, startup acceptance, Azure certification, marketplace approval, customer deployment, or procurement approval.

Diligence manifest

What is ready, what needs qualified review, and what still needs external evidence.

SCRIMED Strategic Investor Outreach is an internal, evidence-based preparation layer. It does not imply that any named organization has reviewed, endorsed, partnered with, funded, accepted, or committed to SCRIMED. Official startup and partner programs are ecosystem paths, not assumed investment offers. External decks, financial claims, valuation language, customer proof, securities communications, and partnership terms require founder approval plus qualified legal, finance, accounting, customer-permission, and claim review as applicable.

evidence-ready

One-company narrative and strategic wedge

Approve a concise category thesis and one primary entry workflow for every meeting.

Founder + Product Strategy
  • Category: company
  • Evidence: /investor-readiness, /healthcare-intelligence-os, /product
  • Boundary: No trillion-dollar valuation, market leadership, or guaranteed-growth claim.
evidence-ready

Working product, PayerIQ workflow, and governed work control plane

Retain deterministic smoke, build, and durable lifecycle evidence for each outreach packet.

Product + Engineering
  • Category: product
  • Evidence: /documentation-before-authorization, /scrimed-work, /demos
  • Boundary: Synthetic/no-PHI product evidence is not live clinical or payer production proof.
evidence-ready

Clinical boundaries, human review, verification, and rollback

Attach current NO-GO boundaries and the approval-path matrix to the diligence room.

Clinical Safety + TrustOps
  • Category: safety
  • Evidence: /trust-os, /clinical-robustness-lab, /risk-register
  • Boundary: No autonomous diagnosis, treatment, prescribing, imaging interpretation, or live-care authority.
external-evidence-required

AAL2, RBAC, tenant isolation, immutable evidence, and secure SDLC

Complete independent penetration testing, evidence review, incident exercises, and approved control-owner attestations.

Security + Platform
  • Category: security
  • Evidence: /trust-center, /pilot-workspace/access, /buyer-release-control-run
  • Boundary: Security readiness is not SOC 2, HIPAA certification, penetration-test assurance, or zero-risk status.
qualified-review-required

Pilot offer, ICP, pricing logic, sales motion, and measured outcome plan

Replace modeled assumptions with permissioned cohort metrics and a finance-reviewed measurement methodology.

Revenue + Finance
  • Category: commercial
  • Evidence: /pilot-demo-commercial-readiness, /pricing, /growth-engine
  • Boundary: No customer, revenue, savings, reimbursement, conversion, or margin guarantee.
qualified-review-required

Use of funds, runway, unit economics, cap table, and scenario model

Prepare a reconciled model, source assumptions, cap table, and board-approved use-of-funds plan.

Founder + qualified Finance/Accounting
  • Category: finance
  • Evidence: /capital-vitality, /public-market-readiness, /enterprise-business-ops
  • Boundary: No audited-financial, valuation, return, revenue, or profitability assurance.
qualified-review-required

Entity, IP, securities path, privacy terms, and investor disclosures

Complete entity/IP review and approve the offering exemption, deck legends, data-room access, and outreach language.

Founder + qualified Counsel
  • Category: legal
  • Evidence: /enterprise-business-ops, /approvals-readiness
  • Boundary: This registry is not legal advice, an offer to sell securities, or solicitation.
external-evidence-required

Intended use, clinical validation, privacy, interoperability, and regulatory path

Approve intended-use boundaries and execute the required validation, privacy, security, interoperability, and regulatory workstream before claims expand.

Clinical Governance + Privacy + Regulatory Counsel
  • Category: clinical-regulatory
  • Evidence: /clinical-authority-readiness, /clinical-production-readiness, /interoperability
  • Boundary: No FDA clearance, HIPAA certification, clinical validation, production connector approval, or customer go-live claim.

Pitch architecture

A twelve-question deck earns the next diligence step.

01SCRIMED: Why healthcare needs an intelligence operating system instead of another chatbot
02The workflow problem: Where clinical and administrative work loses time, evidence, and continuity
03The entry wedge: Why documentation-before-authorization is a measurable, bounded starting point
04The product: How SCRIMED turns registered evidence into governed work artifacts
05Architecture: How models, agents, context, tools, verification, and approvals remain separable
06Trust and safety: Why consequential actions fail closed
07Proof: What works now and what remains gated
08Market and buyer: Who buys first, why, and through which pilot
09Business model: How pricing captures workflow value while protecting margin
10Defensibility: How healthcare workflow structure, evidence, governance, and outcome learning compound
11Milestones and capital: What the next capital tranche de-risks
12Strategic fit: Why this organization is the right ecosystem or strategic counterpart

Controlled outreach

Every external step remains human-approved.

01Evidence-room gap review: Every manifest item has an owner, source, status, and disclosure boundary.
02Company-specific packet: One thesis, one ask, four to six proof routes, and named blocked claims are approved.
03Legal and finance review: Deck legends, securities path, financial model, and external claims are approved for intended use.
04Warm-introduction mapping: A permissioned introducer or official program path is selected with no automated outreach.
05Meeting and technical diligence: Questions, evidence requests, owners, and follow-up dates are recorded without sharing protected material prematurely.
06Learning-loop update: Feedback changes a reviewed artifact, test, narrative, or milestone; no autonomous public update.

Weakness relief

Each weakness now has an owner, workaround, proof route, success metric, and graduation gate.

Close the qualified-review and external-evidence items in the strategic diligence manifest, approve one company-specific thesis and ask, then use a permissioned introduction or official startup-program path. Keep securities, valuation, legal, tax, customer, PHI, clinical, certification, partnership, revenue, and outcome claims behind the appropriate human review.

high

Fundraising story can sound like broad ambition instead of investable execution

Multiple strong surfaces exist, but angels and strategics need the narrative compressed into wedge, proof, market, governance, and next capital use.

Use audience-specific packets that link Growth Engine, Capital Vitality, Product Console, Public Market Readiness, and protected Deal Room proof.
  • Owner: Founder + Capital Operations + qualified counsel
  • Workaround: Use readiness-only investor packets until a counsel-reviewed fundraising deck, data room, and exemption path are approved.
  • Metric: Each investor meeting maps to one audience packet, one proof route set, one ask boundary, and one counsel-review status.
  • Gate: Approved investor materials, controlled data room, qualified securities counsel review, and founder-approved use-of-funds narrative.
  • Proof: /capital-vitality, /growth-engine, /public-market-readiness, /pilot-deal-room
high

Competitive differentiation can be diluted by generic AI healthcare language

Healthcare AI buyers hear many model-wrapper pitches; SCRIMED needs the proof to foreground workflow intelligence, governance, and buyer diligence.

Lead with Healthcare Intelligence OS, AgentOS, Atlas, TrustOS, no-PHI synthetic validation, and release-control evidence.
  • Owner: Founder + Product Marketing + Claim Guard
  • Workaround: Replace generic AI phrases with proof-backed SCRIMED infrastructure claims and route every public claim through Claim Guard.
  • Metric: Every pitch section references at least one proof route and one retained boundary.
  • Gate: Counsel-reviewed positioning guide plus approved claim library for investor, buyer, press, and partner use.
  • Proof: /healthcare-intelligence-os, /agents, /atlas, /trust-os, /qa-claim-guard
high

Enterprise credibility depends on legal, finance, accounting, and deal controls being visible

Large corporate and private investors will test whether SCRIMED can handle contracts, margin, revenue recognition, tax routing, and board-grade evidence.

Use Enterprise Business Ops, Capital Vitality, Public Market Readiness, and protected finance methodology gates.
  • Owner: Finance + Legal Ops + Revenue Operations
  • Workaround: Keep all finance, tax, accounting, legal, revenue recognition, and contract language in qualified-review mode before external release.
  • Metric: Every enterprise opportunity has package, price floor, scope, approval owner, margin exposure, and review status.
  • Gate: Qualified legal/accounting/tax review completed for templates, SOWs, revenue methodology, and board/investor materials.
  • Proof: /enterprise-business-ops, /public-market-readiness, /pricing, /capital-vitality
medium

Faith-based clinic opportunity needs mission alignment without implying endorsement or nonprofit tax conclusions

Faith-based clinics may value access, trust, affordability, and stewardship, but public language must avoid religious endorsement, tax advice, or donor solicitation claims.

Use a mission-aligned clinic packet that emphasizes no-PHI workflow intelligence, safety, stewardship, and affordability controls.
  • Owner: Founder + FaithCore + qualified nonprofit counsel
  • Workaround: Keep faith-based clinic messaging as buyer-readiness and partnership-readiness language until counsel reviews nonprofit, donor, grant, and tax implications.
  • Metric: Each faith-based clinic conversation has mission fit, workflow pain, data boundary, review owner, and nonprofit/tax review status.
  • Gate: Qualified counsel approves nonprofit, donor, grant, church-affiliated clinic, and charitable-use language before external fundraising or partnership claims.
  • Proof: /faithcore, /market-activation, /client-onboarding, /limitations-workarounds
medium

Buyer-specific proof is strong but release controls can slow momentum

Protected evidence improves trust, but investors and buyers may ask for named customer proof before customer permission and release gates exist.

Use metadata-only proof summaries, public route evidence, and protected release-control chain before buyer-specific artifacts move.
  • Owner: Buyer Diligence + Release Steward + TrustOps
  • Workaround: Offer non-confidential proof maps and synthetic evidence while buyer-specific artifacts stay inside AAL2 protected workspaces.
  • Metric: External proof requests are resolved with public proof, protected release decision, or blocked-claim explanation within the review SLA.
  • Gate: Customer permission, release decision, reviewer signoff, recipient controls, and access-log reconciliation retained.
  • Proof: /pilot-workspace/access, /buyer-release-control-run, /qa-buyer-proof-release, /pilot-evidence
medium

Clinical and PHI boundaries can make the product look less advanced if not framed correctly

No-PHI and no-live-care gates are strengths, but audiences may misread them as lack of ambition unless the staged path is explicit.

Frame synthetic proof, human review, authority readiness, interoperability mapping, and clinical activation gates as the safe path to scale.
  • Owner: Clinical Authority + TrustOS + Product
  • Workaround: Position live data as a gated future stage and make current sellable value about workflow intelligence, governance, and protected readiness.
  • Metric: Every demo and investor packet shows current no-PHI value plus the explicit gates required before live clinical use.
  • Gate: Buyer-specific legal, privacy, security, clinical governance, BAA/DPA, connector, and runtime safety approvals retained.
  • Proof: /clinical-authority-readiness, /health-records, /interoperability, /approvals-readiness
medium

Corporate investors need strategic partnership paths, not only financial upside

Large corporations will look for integration leverage, distribution leverage, defensible workflows, procurement posture, and governance controls.

Package strategic-investor pathways around co-development, channel, deployment profile, interoperability readiness, and protected pilots.
  • Owner: Strategic Partnerships + Legal Ops + Product
  • Workaround: Separate non-binding strategic fit notes from term sheets, exclusivity, reseller economics, data rights, or integration commitments.
  • Metric: Each corporate investor conversation has strategic fit, channel path, integration boundary, data-rights hard stops, and legal review owner.
  • Gate: Counsel-reviewed partnership term sheet, data rights, exclusivity limits, procurement path, and security review plan.
  • Proof: /global-reach, /deployment-profiles, /interoperability, /enterprise-business-ops
high

Private investors will pressure unit economics before real customer cohorts mature

The business can show disciplined readiness, but actual CAC, retention, gross margin, and payback require measured buyer cohorts.

Use Public Market Readiness and Enterprise Business Ops to separate modeled assumptions from measured operating metrics.
  • Owner: Finance + Growth + Board Review
  • Workaround: Label unit economics as readiness assumptions until buyer-approved cohorts, finance methodology, and accounting review exist.
  • Metric: Each metric is tagged as modeled, measured, protected, buyer-approved, or external-review-required.
  • Gate: Finance methodology approved with cohort definitions, margin accounting, customer permission, and board reporting controls.
  • Proof: /public-market-readiness, /enterprise-business-ops, /growth-engine, /sales-attribution
medium

Global and public-sector audiences need region-specific approval paths

Global interest can create overclaim risk if region, procurement, data residency, AI governance, and clinical authority are not separated.

Use Global Certification Readiness, Global Reach, Deployment Profiles, and Limitations Workarounds for region-specific packets.
  • Owner: Global Partnerships + Regional Counsel + Security
  • Workaround: Keep every country, public-sector, or sovereign conversation in preparation mode until regional legal, privacy, security, procurement, and clinical review exist.
  • Metric: Every global opportunity has region, buyer pack, procurement path, data residency assumption, and retained review owners.
  • Gate: Regional counsel, privacy/security reviewers, procurement owner, and deployment profile approval retained before external claims expand.
  • Proof: /global-certification-readiness, /global-reach, /deployment-profiles, /limitations-workarounds
medium

The product surface is powerful but can overwhelm first-time investors or clinic leaders

The platform has many routes and proof systems; audiences need a simple first path matched to their question.

Use this readiness layer as the audience router and keep navigation journeys tied to Product, Proof, Growth, Capital, Trust, and Onboarding.
  • Owner: Product Console + Navigation Owner + Sales Operations
  • Workaround: Route each audience to one packet, one executive brief, one proof ladder, and one next meeting action.
  • Metric: Audience path completion improves: packet opened, proof reviewed, next call scheduled, or disqualified with reason.
  • Gate: Navigation telemetry, CRM source attribution, and buyer/investor feedback show repeatable packet-to-meeting conversion.
  • Proof: /navigation, /product, /client-onboarding, /growth-engine

Competitive edge

The sellable story is healthcare workflow infrastructure with proof, governance, and audience packaging.

edge

Healthcare Intelligence OS rather than single-feature AI

SCRIMED is building governed healthcare intelligence infrastructure for workflow transformation.

Investors see a platform thesis; buyers see a practical route from workflow pain to governed pilots.
  • SCRIMED combines workflow intelligence, AgentOS, Atlas, TrustOS, evidence routing, and buyer diligence into one operating layer.
  • The defensibility is healthcare workflow structure, proof discipline, and trust operations, not raw model access.
  • Platform thesis is not clinical validation, production approval, or investment advice.
  • Proof: /healthcare-intelligence-os, /product, /agents, /atlas
edge

Synthetic-first proof reduces early PHI and procurement friction

SCRIMED can create enterprise learning velocity without crossing live-data gates early.

Health systems and clinics can evaluate value without rushing PHI, EHR, or live-care authority.
  • The company can sell assessment, synthetic pilot, and governance value before live data access.
  • Synthetic validation, fixture discipline, and no-PHI controls create repeatable buyer evidence while competitors wait for data access.
  • Synthetic evidence is not live clinical proof or PHI authorization.
  • Proof: /demos, /pilots, /health-records, /interoperability/evaluations
edge

TrustOS, Claim Guard, and release controls are productized

SCRIMED makes healthcare AI diligence operational instead of ad hoc.

Enterprise buyers can inspect how SCRIMED prevents overclaims, uncontrolled distribution, and unmanaged evidence.
  • Governance is embedded as a product surface with claims boundaries, proof promotion, and buyer release gates.
  • Trust controls compound with every new route and proof packet.
  • Trust readiness is not legal approval, certification, or customer permission.
  • Proof: /trust-os, /qa-claim-guard, /buyer-release-control-run, /pilot-workspace/access
edge

Audience-specific packaging for capital and clinics

SCRIMED can speak to capital, clinics, and enterprise buyers without collapsing their risks into one generic pitch.

Each audience receives the proof and limits that match its decision process.
  • The platform now separates angel, corporate strategic, private investor, faith-based clinic, public-sector, payer, provider, and global partner readiness.
  • Audience-routing discipline reduces founder bottleneck and improves conversion quality.
  • Audience readiness is not investor suitability, solicitation, or procurement approval.
  • Proof: /investor-audience-readiness, /growth-engine, /capital-vitality, /client-onboarding
edge

FaithCore and mission-aligned clinic pathway

SCRIMED can help mission-led clinics improve operational capacity without forcing enterprise-style procurement first.

Mission-led clinics can evaluate workflow intelligence in a way that respects trust and resource constraints.
  • Faith-based clinic positioning is handled as stewardship, access, affordability, and safety readiness rather than religious endorsement.
  • The positioning gives SCRIMED a differentiated community clinic wedge while retaining nonprofit and tax review boundaries.
  • Faith-based readiness is not tax advice, donor advice, religious endorsement, or nonprofit approval.
  • Proof: /faithcore, /market-activation, /client-onboarding, /investor-audience-readiness
edge

Enterprise business operations are visible before scale

SCRIMED is preparing for enterprise-grade growth before enterprise complexity arrives.

Large investors can see the operating controls needed for enterprise contracts and responsible growth.
  • Deal desk, margin, legal, accounting, tax, revenue operations, and approval roles are explicit.
  • Commercial discipline protects margin and reduces diligence friction.
  • Operating controls are not legal, accounting, tax, audited finance, or contract advice.
  • Proof: /enterprise-business-ops, /public-market-readiness, /pricing, /capital-vitality
edge

Global certification readiness without premature approval claims

SCRIMED can scale globally only through disciplined regional evidence, not shortcut claims.

Corporate strategics and global partners can inspect how SCRIMED will approach region, AI governance, privacy, security, and clinical gates.
  • Domestic and global approval paths are mapped while keeping authority claims blocked.
  • Preparation reduces future expansion friction and buyer skepticism.
  • Global readiness is not regional legal approval, certification, conformity, or procurement approval.
  • Proof: /global-certification-readiness, /global-reach, /deployment-profiles
edge

Continuous review and innovation loops

SCRIMED compounds through review, evidence, and controlled innovation.

Investors see learning velocity; buyers see a safer path to accuracy improvement.
  • 24/7 review, audit, source attribution, QA loops, and internal innovation research are separated from autonomous production authority.
  • The review system turns mistakes and bottlenecks into operational learning rather than hidden risk.
  • Review loops are not managed SOC/MDR coverage, autonomous remediation, or public quantum capability.
  • Proof: /continuous-review-audit, /operational-efficiency, /limitations-workarounds

Audience packets

Each target audience gets a distinct value story, diligence packet, next move, and blocked-claim list.

ready-now

Angel investors and early healthcare operators

Can SCRIMED explain the wedge, why now, and why this founder-led execution can win?

A governed synthetic-pilot wedge into healthcare workflow intelligence, with proof routes already live.
  • Pitch: Lead with category clarity, painful workflow targets, trust moat, no-PHI pilot speed, and specific use of funds.
  • Packet: Category thesis, Founder-led sales plan, Synthetic pilot examples, Use-of-funds draft
  • Next: Run angel conversations through a counsel-reviewed deck and readiness-only data room before any offering language.
  • Review: Qualified securities counsel before solicitation, SAFE/equity note, valuation, or offering documents.
  • Blocked: Guaranteed return, Investment recommendation, Approved securities offer, Valuation certainty
  • Proof: /product, /growth-engine, /capital-vitality, /healthcare-intelligence-os
package-next

Large corporate strategic investors

Can SCRIMED become strategically useful through distribution, workflow, data, integration, or platform leverage?

Strategic partner pathways around health-system operations, payer workflows, interoperability, deployment profiles, and governance infrastructure.
  • Pitch: Lead with strategic fit, protected pilot path, co-development boundary, data-rights hard stops, and channel economics review.
  • Packet: Strategic-fit memo, Integration boundary map, Deployment profile, Partner economics review
  • Next: Prepare a non-binding strategic partnership memo before any exclusivity, reseller, integration, or data-rights term sheet.
  • Review: Qualified counsel, security, privacy, procurement, and finance review.
  • Blocked: Partnership approved, Exclusive rights granted, Production connector approved, Data rights assigned
  • Proof: /global-reach, /deployment-profiles, /interoperability, /enterprise-business-ops
external-review-required

Private investors and growth-equity reviewers

Can SCRIMED show market size, unit economics, enterprise pricing, margin control, and repeatable growth?

Operating-readiness proof for enterprise packages, price floors, buyer segments, proof ladder, and finance methodology gates.
  • Pitch: Separate measured signals from modeled assumptions and show a path from paid assessments to synthetic pilots to enterprise licenses.
  • Packet: KPI stack, Unit-economics assumptions, Pricing architecture, Deal-desk controls
  • Next: Move private investor review through finance-methodology and counsel-review packets before external metric claims.
  • Review: Qualified finance/accounting/legal review before KPI, valuation, securities, revenue, or margin claims.
  • Blocked: Audited metrics, Guaranteed margin, Guaranteed revenue, Valuation assurance
  • Proof: /public-market-readiness, /enterprise-business-ops, /pricing, /growth-engine
package-next

Faith-based clinics and mission-led clinic investors

Can SCRIMED improve access, stewardship, documentation, and clinic capacity without violating trust boundaries?

A mission-aligned no-PHI assessment and synthetic pilot path for clinics operating under resource, trust, and affordability constraints.
  • Pitch: Lead with stewardship, safer workflow review, affordability-aware deployment, human oversight, and no-PHI early evaluation.
  • Packet: Mission-fit brief, No-PHI clinic workflow assessment, Stewardship value map, Nonprofit/tax review checklist
  • Next: Offer a human-reviewed clinic discovery path and keep donor, nonprofit, grant, and tax language behind qualified review.
  • Review: Qualified nonprofit, tax, legal, privacy, and clinical governance review.
  • Blocked: Tax-deductible investment, Religious endorsement, IRS approval, Donor outcome guarantee
  • Proof: /faithcore, /client-onboarding, /market-activation, /health-records
ready-now

Health system executives

Can SCRIMED relieve workflow pain without forcing immediate live data exposure?

Paid workflow intelligence assessment and synthetic pilot pathway with governance, evidence, and production-readiness gates.
  • Pitch: Lead with operational pain, workflow evidence, no-PHI evaluation, leadership decision pack, and staged implementation plan.
  • Packet: Workflow assessment scope, Synthetic pilot plan, Governance report, Implementation blueprint
  • Next: Route qualified sponsors into Pilot Intake and attach one workflow target, success metric, and review team.
  • Review: Buyer clinical, privacy, security, legal, and implementation review before protected or live stages.
  • Blocked: Clinical outcome guaranteed, PHI approved, Production integration approved, Autonomous care
  • Proof: /product, /demos, /pilots, /pilot-deal-room
package-next

Payers and revenue-cycle buyers

Can SCRIMED find denial, documentation, prior-auth, and evidence gaps without final billing action?

Synthetic revenue workflow pilots that surface evidence gaps, policy friction, and workflow pressure for human review.
  • Pitch: Lead with operational intelligence, not reimbursement guarantees, and keep final payer submission blocked.
  • Packet: Revenue workflow demo, Evidence-gap map, Policy-friction packet, Finance methodology boundary
  • Next: Package one no-PHI revenue workflow demonstration around a buyer-approved value metric.
  • Review: Buyer finance, reimbursement, legal, compliance, and privacy review.
  • Blocked: Reimbursement guaranteed, Payer submission approved, Revenue lift guaranteed, Final billing action
  • Proof: /workflows/results, /atlas, /pricing, /public-market-readiness
external-review-required

Public-sector, grant, and community health funders

Can SCRIMED support access, equity, rural health, or public capacity with governed evidence?

Community and public-sector readiness packets around safe workflow intelligence, regional approvals, procurement, and reporting controls.
  • Pitch: Lead with public-good workflows, no-PHI readiness, governance, transparency, and region-specific review.
  • Packet: Grant-readiness brief, Regional review map, Procurement path, Impact measurement boundary
  • Next: Prepare grant or public-sector language only after procurement, regional legal, privacy, security, and reporting review.
  • Review: Qualified grant, procurement, legal, privacy, public-sector, and regional review.
  • Blocked: Government endorsement, Grant approved, Regional approval, Certified public impact
  • Proof: /global-reach, /global-certification-readiness, /deployment-profiles, /market-activation
ready-now

Clinician advisors and medical leadership

Can clinicians guide the product without taking responsibility for unsafe automation?

Clinical authority readiness, human-review gates, blocked action lists, and synthetic workflow review.
  • Pitch: Lead with clinician oversight, workflow design, safety constraints, and explicit no-live-care boundary.
  • Packet: Clinical advisory scope, Blocked-action register, Review protocol, Safety escalation path
  • Next: Invite advisors into bounded workflow review and authority-readiness work before any live-care pilot.
  • Review: Clinical governance, legal, privacy, and conflict-of-interest review.
  • Blocked: Medical advice, Treatment recommendation, Clinical validation, Live-care authority
  • Proof: /clinical-authority-readiness, /clinical-care-activation, /qa-evidence, /trust-center
external-review-required

Global partners and regional distributors

Can SCRIMED adapt by region without overclaiming approvals or procurement readiness?

Region-specific buyer packs, deployment profiles, localization paths, and retained approval gates.
  • Pitch: Lead with local readiness discipline, evidence packets, data residency review, and no premature conformity claims.
  • Packet: Regional buyer pack, Deployment profile, Approval-gate map, Partner channel review
  • Next: Qualify partner fit and route regional claims through local counsel, security, privacy, procurement, and clinical review.
  • Review: Qualified regional legal, privacy, security, procurement, and clinical reviewers.
  • Blocked: Regional certification, Procurement approved, Conformity approved, Data residency approved
  • Proof: /global-reach, /deployment-profiles, /global-certification-readiness, /limitations-workarounds
ready-now

Enterprise innovation and transformation sponsors

Can SCRIMED create a credible first project that does not get trapped in procurement?

Fixed-scope assessment and synthetic pilot packages with clear governance, proof, and expansion gates.
  • Pitch: Lead with small, governed workflow wins that produce an executive decision packet and future implementation plan.
  • Packet: Assessment packet, Synthetic pilot scope, Meeting cadence, Executive decision brief
  • Next: Use Client Onboarding to move from discovery to demo, workshop, pilot scope, and follow-up without unreviewed promises.
  • Review: Buyer sponsor, security, privacy, legal, finance, and implementation owner review.
  • Blocked: Procurement approved, Savings guaranteed, Customer permission assumed, Production support guaranteed
  • Proof: /offerings, /client-onboarding, /growth-engine, /pilot

Readiness gates

Official and internal guardrails keep fundraising, faith-clinic, and diligence work reviewable.

Founder + qualified securities counsel

Private offering and solicitation review

Keep angel, private, corporate, SAFE, note, and equity conversations behind counsel-reviewed materials and a selected exemption path.

SEC capital-raising and private offering guidance
  • Source: https://www.sec.gov/resources-small-businesses/capital-raising-building-blocks/exempt-offerings
  • Hard stop: No securities offering, solicitation, valuation, or investor suitability language leaves readiness mode without counsel review.
Capital Operations + qualified counsel

Accredited investor handling

Prepare investor routing and diligence questions that distinguish readiness discussions from offering materials.

SEC accredited investor guidance
  • Source: https://www.sec.gov/resources-small-businesses/capital-raising-building-blocks/accredited-investors
  • Hard stop: Do not imply anyone is qualified, suitable, or approved to invest through this product surface.
Founder + qualified securities counsel

Form D timing awareness

Flag that private fundraising processes may require notice filing after first securities sale, depending on the exemption path.

SEC Form D guidance
  • Source: https://www.sec.gov/resources-small-businesses/capital-raising-building-blocks/what-form-d
  • Hard stop: SCRIMED public pages do not file Form D or approve fundraising documents.
Founder + qualified securities counsel

Crowdfunding boundary

Keep community, clinic, mission, and donor-adjacent conversations separated from any crowdfunding campaign language.

SEC Regulation Crowdfunding guidance
  • Source: https://www.sec.gov/resources-small-businesses/capital-raising-building-blocks/regulation-crowdfunding
  • Hard stop: No crowdfunding offer, platform claim, or public investment campaign is approved by this readiness page.
FaithCore + qualified nonprofit counsel

Faith-based clinic and nonprofit tax boundary

Route church-affiliated, nonprofit, charitable, grant, donor, and mission-led clinic language through qualified nonprofit and tax review.

IRS 501(c)(3) exemption requirements
  • Source: https://www.irs.gov/charities-non-profits/charitable-organizations/exemption-requirements-501c3-organizations
  • Hard stop: Do not claim tax deductibility, charitable approval, donor benefit, or nonprofit compliance without qualified review.
Finance + accounting reviewers

Financial reporting and metric methodology

Separate modeled investor metrics from measured, buyer-approved, protected, or externally reviewed operating metrics.

SCRIMED Public Market Readiness
  • Source: /public-market-readiness
  • Hard stop: No audited financial reporting, valuation, margin guarantee, or revenue guarantee claim.
TrustOps + Claim Guard

Claim Guard before public use

Run investor, buyer, faith-clinic, public-sector, partner, and PR language through blocked-claim controls.

SCRIMED QA Claim Guard
  • Source: /qa-claim-guard
  • Hard stop: No unsupported clinical, compliance, certification, revenue, investment, customer, or partnership claim.
Release Steward + Buyer Diligence

Protected diligence release

Keep buyer-specific, investor-specific, and customer-specific evidence in protected release lanes until permissions and controls exist.

SCRIMED Buyer Release Control Runbook
  • Source: /buyer-release-control-run
  • Hard stop: No named customer proof, confidential artifact, or protected packet is released without retained approval chain.